NO942913L - Fremgangsmåte for fremstilling av inflammatoriske dermatoser - Google Patents

Fremgangsmåte for fremstilling av inflammatoriske dermatoser

Info

Publication number
NO942913L
NO942913L NO942913A NO942913A NO942913L NO 942913 L NO942913 L NO 942913L NO 942913 A NO942913 A NO 942913A NO 942913 A NO942913 A NO 942913A NO 942913 L NO942913 L NO 942913L
Authority
NO
Norway
Prior art keywords
corticosteroid
preparation
retinoid
treatment
healing
Prior art date
Application number
NO942913A
Other languages
English (en)
Norwegian (no)
Other versions
NO942913D0 (enExample
Inventor
Albert M Kligman
Original Assignee
Albert M Kligman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert M Kligman filed Critical Albert M Kligman
Publication of NO942913D0 publication Critical patent/NO942913D0/no
Publication of NO942913L publication Critical patent/NO942913L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO942913A 1992-02-07 1994-08-05 Fremgangsmåte for fremstilling av inflammatoriske dermatoser NO942913L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83282892A 1992-02-07 1992-02-07
PCT/US1993/001043 WO1993015740A1 (en) 1992-02-07 1993-01-29 Methods of treating inflammatory dermatoses

Publications (2)

Publication Number Publication Date
NO942913D0 NO942913D0 (enExample) 1994-08-05
NO942913L true NO942913L (no) 1994-10-05

Family

ID=25262717

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942913A NO942913L (no) 1992-02-07 1994-08-05 Fremgangsmåte for fremstilling av inflammatoriske dermatoser

Country Status (12)

Country Link
US (1) US5998395A (enExample)
EP (1) EP0625045A4 (enExample)
JP (1) JP2927961B2 (enExample)
KR (1) KR100282575B1 (enExample)
AU (1) AU667519B2 (enExample)
CA (1) CA2129114A1 (enExample)
CZ (1) CZ188394A3 (enExample)
FI (1) FI943625A7 (enExample)
NO (1) NO942913L (enExample)
NZ (1) NZ249379A (enExample)
WO (1) WO1993015740A1 (enExample)
ZA (1) ZA93811B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344448B1 (en) 1992-09-11 2002-02-05 Stb Family Limited Partnership Composition for the treatment of hair loss
DE69330429T2 (de) * 1992-09-11 2002-05-16 Sandra Brown Verfahren zur behandlung von haarausfall
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
DE69623612T2 (de) * 1995-05-05 2003-05-15 Mark S. Braiman Behandlung der psoriasis mit 11-cis-retinsäure
US6008254A (en) 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
WO1999020309A1 (en) * 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
FR2761600B1 (fr) * 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
ES2310549T3 (es) * 2000-05-09 2009-01-16 Kaneka Corporation Composiciones dermicas que contienen coenzima q como principio activo.
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
KR20020027198A (ko) * 2000-10-02 2002-04-13 차알스 제이. 메츠 염증과 홍반의 완화방법
FR2823117A1 (fr) * 2000-11-14 2002-10-11 Pharmascience Lab Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
US20020146744A1 (en) * 2001-03-02 2002-10-10 Lawandy Nabil M. Combinatorial chemistry and compound identification system
ES2188426B1 (es) * 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
US20030199488A1 (en) * 2002-04-23 2003-10-23 Trotta Gina M. Treatment of hyperproliferative disorders/inflammatory dermatoses
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US8232304B2 (en) * 2002-10-24 2012-07-31 G & R Pharmaceuticals, Llc Antifungal formulations
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
AU2004292445B2 (en) * 2003-11-21 2010-02-04 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
EP1727530A4 (en) * 2004-02-19 2009-10-21 Chemaphor Inc TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
HUE041585T2 (hu) 2004-09-28 2019-05-28 Avivagen Inc Kompozíciók és eljárások súlygyarapodás és táplálék konverzió elõsegítésére
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
KR101762753B1 (ko) 2007-10-26 2017-08-04 아비바젠 인코포레이티드. 면역반응을 증강시키기 위한 조성물 및 그 방법
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
CA2975313C (en) 2009-04-30 2020-06-30 Avivagen Inc. Methods and compositions for improving the health of animals
US20120283235A1 (en) 2009-10-20 2012-11-08 Discovery Partners Llc Dermatologic and Cosmetic Compositions
ES2378028B1 (es) 2012-02-22 2013-02-18 Ignacio Umbert Millet Composición cosmética para el rejuvenecimiento de la piel y procedimiento y usos correspondientes
MX392053B (es) * 2017-09-28 2025-03-21 Johnson & Johnson Consumer Inc Composiciones cosmeticas y metodo para tratar la piel
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4126693A (en) * 1975-11-03 1978-11-21 Johnson & Johnson Retinoic acid derivatives in the treatment of acne
ZA77678B (en) * 1977-02-07 1978-09-27 S Fourie Pharmaceutical composition and use thereof
US4487782A (en) * 1982-03-26 1984-12-11 Ortho Pharmaceutical Corporation Topical treatment of non-inflammatory acne
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
US4889847A (en) * 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy

Also Published As

Publication number Publication date
KR950700069A (ko) 1995-01-16
AU667519B2 (en) 1996-03-28
WO1993015740A1 (en) 1993-08-19
FI943625L (fi) 1994-08-04
EP0625045A4 (en) 1995-01-18
ZA93811B (en) 1993-09-10
NZ249379A (en) 1998-07-28
EP0625045A1 (en) 1994-11-23
NO942913D0 (enExample) 1994-08-05
AU3585493A (en) 1993-09-03
FI943625A0 (fi) 1994-08-04
CZ188394A3 (en) 1996-02-14
JP2927961B2 (ja) 1999-07-28
US5998395A (en) 1999-12-07
KR100282575B1 (ko) 2001-02-15
JPH07505617A (ja) 1995-06-22
FI943625A7 (fi) 1994-08-04
CA2129114A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
NO942913L (no) Fremgangsmåte for fremstilling av inflammatoriske dermatoser
DK0682514T3 (da) Anvendelse af lokalanæstetiske midler til fremstilling af et lægmiddel til behandling af bronchial astma
DK0719145T3 (da) Nitrogenoxiddonorpræparat til behandling af anale lidelser
RU2008101791A (ru) Заживление ран
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
DE59407336D1 (de) Verwendung von Cineol oder Menthol zur Behandlung von Asthma
EP4427738A3 (en) Dosing protocols and regimens for aminosterol treatment
PE20242201A1 (es) Tratamiento de neurofibromas cutaneos con mirdametinib
ATE421877T1 (de) Verwendung von totarol zur behandlung von pruritus
DE69519582D1 (de) Kontrolle des haarwuchses
ATE151977T1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
NO982935L (no) Hyaluronsyre reseptor bindemiddel og anvendelse derav
PL334679A1 (en) Application of dichlorobenzyl alcohol in production of preparations useful in locally treating inflammatory states as well as preparation useful in loacally treating inflammatory states as well as preparation containing such alcohol
IL318374A (en) Methods of administering nalbuphine
WO2023019095A3 (en) Momelotinib combination therapy
DE69628153D1 (de) Verwendung von natriumchlorid zur behandlung der akne und/oder der rosacea
BR0012121A (pt) Derivado de aminotetralina para terapia de doenças cardiovasculares
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.
RU2696532C2 (ru) Способ моделирования лимфовенозной недостаточности в тазовых органах
Pacurari et al. Inhibiting NF-κB Attenuates H2O2-Induced MMP-9 and MMP-12 Expression
Khanna et al. L-valine as an anti-inflammatory agent
CN111803568A (zh) 一种治疗蜂窝织炎的中药外用制剂
JPH02142734A (ja) プロポリス併用皮膚病治療方法
MOHIUDDIN Menerganj Dispensary, District Purnea, Bihar